DDInter119 DDInter462
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Dabrafenib {u} (Compound) binds {v} (Gene) SLCO1B3
Dabrafenib {u} (Compound) upregulates {v} (Gene) PSAT1
Dabrafenib {u} (Compound) is included by {v} (Pharmacologic Class) Organic Anion Transporter 3 Inhibitors
Dabrafenib {u} (Compound) downregulates {v} (Gene) LIG1
Dabrafenib {u} (Compound) causes {v} (Side Effect) Abdominal pain
Dabrafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Dabrafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Levacetylmethadol
Dabrafenib (Compound) binds SLCO1B3 (Gene)
Dabrafenib (Compound) upregulates PSAT1 (Gene)
Dabrafenib (Compound) is included by Organic Anion Transporter 3 Inhibitors (Pharmacologic Class)
Dabrafenib (Compound) downregulates LIG1 (Gene)
Dabrafenib (Compound) causes Abdominal pain (Side Effect)
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Dabrafenib may lead to a major life threatening interaction when taken with Levacetylmethadol